Duopharma Biotech Bhd Total Assets
Duopharma Biotech Bhd total assets. Based on the latest financial reports, Duopharma Biotech Bhd (7148) holds total assets worth RM1.46 Billion MYR (≈ $365.99 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Duopharma Biotech Bhd for the company's overall valuation and market capitalisation.
Total Assets of Duopharma Biotech Bhd (2006–2025)
Total assets of Duopharma Biotech Bhd from 2006 to 2025. This chart illustrates how Duopharma Biotech Bhd's total assets have evolved over time, based on quarterly financial data. See latest Duopharma Biotech Bhd stock price today for real-time trading data and today's change.
Duopharma Biotech Bhd - Asset Composition Analysis
Duopharma Biotech Bhd Total Assets Breakdown (December 2025)
Duopharma Biotech Bhd total assets breakdown as of December 2025. Duopharma Biotech Bhd's total assets of RM1.46 Billion consist of 56.6% current assets and 43.4% non-current assets.
| Asset Category | Amount (MYR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | RM0.00 | 20.1% |
| Accounts Receivable | RM235.37 Million | 16.3% |
| Inventory | RM293.17 Million | 20.2% |
| Property, Plant & Equipment | RM0.00 | 0.0% |
| Intangible Assets | RM36.88 Million | 2.6% |
| Goodwill | RM0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Duopharma Biotech Bhd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Duopharma Biotech Bhd (7148) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Duopharma Biotech Bhd's current assets represent 56.6% of total assets in 2025, a decrease from 64.9% in 2006.
- Cash Position: Cash and equivalents constituted 20.1% of total assets in 2025, down from 34.2% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is inventory at 20.2% of total assets.
Duopharma Biotech Bhd Competitors by Total Assets
Key competitors of Duopharma Biotech Bhd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
Duopharma Biotech Bhd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.80 | 3.98 | 2.11 |
| Quick Ratio | 1.79 | 2.65 | 1.17 |
| Cash Ratio | 0.00 | 1.32 | 0.43 |
| Working Capital | RM542.75 Million | RM575.91 Million | RM282.54 Million |
Duopharma Biotech Bhd - Advanced Valuation Insights
This section examines the relationship between Duopharma Biotech Bhd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.42 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | 5.2% |
| Total Assets | RM1.45 Billion |
| Market Capitalization | $268.08 Million USD |
Valuation Analysis
Below Book Valuation: The market values Duopharma Biotech Bhd's assets below their book value (0.19x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Duopharma Biotech Bhd's assets grew by 5.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Duopharma Biotech Bhd (2006–2025)
The table below shows the annual total assets of Duopharma Biotech Bhd from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | RM1.45 Billion ≈ $363.62 Million |
+5.18% |
| 2024-12-31 | RM1.38 Billion ≈ $345.72 Million |
+2.37% |
| 2023-12-31 | RM1.35 Billion ≈ $337.72 Million |
+10.08% |
| 2022-12-31 | RM1.22 Billion ≈ $306.78 Million |
+4.96% |
| 2021-12-31 | RM1.16 Billion ≈ $292.27 Million |
+9.99% |
| 2020-12-31 | RM1.06 Billion ≈ $265.74 Million |
+15.07% |
| 2019-12-31 | RM919.80 Million ≈ $230.93 Million |
+9.97% |
| 2018-12-31 | RM836.38 Million ≈ $209.99 Million |
+18.59% |
| 2017-12-31 | RM705.24 Million ≈ $177.06 Million |
+6.62% |
| 2016-12-31 | RM661.46 Million ≈ $166.07 Million |
+4.42% |
| 2015-12-31 | RM633.45 Million ≈ $159.04 Million |
+184.72% |
| 2014-12-31 | RM222.48 Million ≈ $55.86 Million |
+8.18% |
| 2013-12-31 | RM205.65 Million ≈ $51.63 Million |
+3.85% |
| 2012-12-31 | RM198.03 Million ≈ $49.72 Million |
+0.26% |
| 2011-12-31 | RM197.52 Million ≈ $49.59 Million |
+0.53% |
| 2010-12-31 | RM196.48 Million ≈ $49.33 Million |
+13.33% |
| 2009-12-31 | RM173.36 Million ≈ $43.53 Million |
+15.28% |
| 2008-12-31 | RM150.38 Million ≈ $37.76 Million |
+18.10% |
| 2007-12-31 | RM127.33 Million ≈ $31.97 Million |
-19.92% |
| 2006-12-31 | RM159.01 Million ≈ $39.92 Million |
-- |
About Duopharma Biotech Bhd
Duopharma Biotech Berhad, together with its subsidiaries, researches, develops, manufactures, markets, sells, imports, and distributes pharmaceutical products and medicines in Malaysia and internationally. It offers consumer healthcare products, including vitamins, minerals, and supplements under the Flavettes, PROVITON, PROVITON STR, CHAMPS, and Naturalle brand names; analgesics and antitussives… Read more